Medical/Pharmaceuticals
Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy
* ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors. * Phase 1 Clinical Study Expected to Begin in H2 2024. ALAMEDA, Calif. and TAIPEI, Feb. 4, 2024 /PRNewswire/ -- Acepodia (6976:TT), a clinical stag...
2024-02-05 08:00
2982
Blossoming Flowers at the Top of the Biopharmaceutical Tree -- Reflections on the Flourishing of Sanyou's 4C Business
SHANGHAI, Feb. 2, 2024 /PRNewswire/ -- In 1996, MDS Pharma Service invested in and established the first true Contract Research Organization (CRO) inChina, dedicated to clinical trial business for new drugs. This marked the official launch of the CRO industry inChina. The concept of CRO originat...
2024-02-03 08:00
3548
Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED
* Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor * Inmagene retains rights to develop and commerciali...
2024-02-02 22:00
3374
2024 Global Appeal Calls for Well-Informed Public to 'Break Chains of Discrimination' against Leprosy
TOKYO, Feb. 1, 2024 /PRNewswire/ -- Sasakawa Leprosy (Hansen's Disease) Initiative has partnered with the World Health Organization to co-host the launch of the 2024 Global Appeal to end stigma and discrimination against persons affected by leprosy at WHO headquarters inGeneva on January 31, 2024...
2024-02-01 14:00
2829
Promising Clinical Results on the World's First Use of BCMA CAR-T to Treat Immune Mediated Necrotizing Myopathy (IMNM) Published on the Proceedings of the National Academy of Sciences (PNAS)
SHANGHAI, NANJING, China and SAN JOSE, Calif., Jan. 31, 2024 /PRNewswire/ -- On Jan. 30, 2024, PNAS published the research paper titled "Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR T-cell therapy." The paper analyzed results using the fully human B ...
2024-02-01 11:07
2883
Anbogen Secures 12.5 Million in Series A Funding, Advancing Precision Oncology Drug Development
TAIPEI, Jan. 31, 2024 /PRNewswire/ -- Anbogen Therapeutics, a clinical-stage biotechnology company specializing in groundbreaking cancer drug development, today announced the successful completion of its Series A funding round. The lead investor is China Development Industrial Bank (CDIB), with s...
2024-02-01 00:00
3168
Crystal Pharmatech's CDMO Business Unit - Crystal Formulations Services Successfully Passed EU QP Audit
SUZHOU, China, Jan. 31, 2024 /PRNewswire/ -- Recently, Crystal Formulations Services (CFS), the CDMO Business Unit of Crystal Pharmatech has achieved a significant milestone by successfully passing the on-site audit conducted by the European Qualified Person (QP), evaluating its GMP quality syste...
2024-01-31 21:00
2500
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland
- First manufacturing run successful for MFG7 facility at the Ireland site - Largest manufacturing scale to date achieved by combining four 4,000-liter single-use bioreactors DUNDALK, Ireland, Jan. 31, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Researc...
2024-01-31 17:31
3628
WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development
SHANGHAI, Jan. 30, 2024 /PRNewswire/ -- WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clinical stage biotechnology company renowned for ADC platfor...
2024-01-31 10:43
4220
Universe Pharmaceuticals INC Reports Fiscal Year 2023 Financial Results
JI'AN, China, Jan. 30, 2024 /PRNewswire/ -- Universe Pharmaceuticals INC ("Universe Pharmaceuticals" or the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor inChina, today announced its financial results for the fiscal year endedSeptember 30, 2023. Mr. Gang Lai, Chairman and C...
2024-01-31 05:30
3874
XtalPi Unveils Ailux: A New Chapter in AI-Powered Biologics Discovery
CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- XtalPi Inc. (XtalPi), a globally leading innovative R&D platform company that harnesses the power of artificial intelligence (AI), quantum physics-based computation, and robotic automation to advance the discovery and evolution of groundbreaking th...
2024-01-30 21:00
3180
Singleron launches the AccuraSCOPE® Single Cell Transcriptome
COLOGNE, Germany, Jan. 30, 2024 /PRNewswire/ -- Singleron Biotechnologies, a leader in single cell multi-omic solutions for precision medicine,announced two new commercial product launches : AccuraSCOPE® Single Cell Transcriptome and Genome Library Kit and the AccuraSCOPE® Single Cell Full-Length...
2024-01-30 18:05
2211
DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor for Immunological Diseases Including IBD and AD
* The nomination of novel Kv1.3 inhibitor DPT0218 for the treatment of various immunological diseases including IBD and AD. • DPT0218 is a gut-restricted, highly potent and selective Kv1.3 inhibitor with excellent in vivo efficacy and safety profile in preclinical studies. * This project fur...
2024-01-30 16:32
3149
Vesicure Therapeutics made notable advancements using exosomes to target KRAS mutation
SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- SiRNA technology offers distinct advantages over conventional approaches, with the potential to target virtually any gene. This technology has emerged as a great strategy for treating a range of diseases, including cancer, viral infections, and genetic...
2024-01-29 21:30
2311
Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma.
SHANGHAI and ROSELAND, N.J., Jan. 29, 2024 /PRNewswire/ -- Oricell Therapeutics (Oricell), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for OriCAR-017 for patients with...
2024-01-29 21:08
3857
Crystal Bio Welcomes Dr. Shiaw-Lin (Billy) Wu as Co-Founder and Chief Scientific Officer
CRANBURY, N.J., Jan. 29, 2024 /PRNewswire/ -- Crystal Bio, an innovative spinout division of Crystal Pharmatech, is excited to announce Dr.Shiaw-Lin (Billy) Wu as its new co-founder and Chief Scientific Officer (CSO). Dr. Wu brings with him more than three decades of experience in the field of...
2024-01-29 21:00
2380
Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders
SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company leading the charge in small activating RNA (saRNA) therapeutics, announces a formal collaboration with University Medical Center Utrecht, affiliated withUtrecht University. This strategic ...
2024-01-29 21:00
2682
Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio™ Transcatheter Aortic Regurgitation Clinical Trial
SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, today announced the completion of patient enrollment and implant...
2024-01-29 21:00
3015
Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, a Bladder Cancer Diagnosis and Management Drug, at the 2024 ASCO-GU
SHANGHAI, Jan. 29, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the release of ...
2024-01-29 16:17
2805
Asieris Presents for the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU
SHANGHAI, Jan. 29, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the first-time ...
2024-01-29 14:05
2766
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
48104
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
2026-10-29 20:03
23790
ROKAE delivers its 10,000th humanoid force-controlled arm
2026-10-27 00:00
20350
